Melatonin and zinc may reduce fatigueEffect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Highly relevant study findings
We conducted a 16-week, randomized, double-blind trial to investigate the impact of melatonin combined with zinc on fatigue symptoms in individuals with chronic fatigue syndrome (ME/CFS).
Our research involved 50 participants, where 24 received the active treatment while 26 were given a placebo.
The results were encouraging, showing a significant reduction in fatigue perception and an improvement in overall quality of life for those taking melatonin and zinc.
While urinary levels of melatonin increased significantly, zinc levels did not show notable differences. Overall, this treatment appears safe and potentially beneficial for managing ME/CFS symptoms.
Read More
We examined the impact of melatonin on 29 patients with chronic fatigue syndrome (CFS) who had a late Dim Light Melatonin onset (DLMO). Over three months, patients took 5 mg of melatonin five hours before their DLMO.
Both before and after the treatment, we measured their fatigue levels using a reliable questionnaire. After treatment, we saw significant improvements in overall fatigue, concentration, motivation, and activity, especially in patients with a later DLMO.
These findings suggest that melatonin could be a helpful option for managing fatigue in individuals with CFS and delayed melatonin secretion.
Read More
Melatonin shows promise in CFSEffect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome.
Relevance: Moderate scientific insight
We investigated how antioxidants, including melatonin, impact chronic fatigue syndrome (CFS) using a mouse model. In our study, mice were subjected to daily swimming, mimicking fatigue symptoms. We found that melatonin, along with other antioxidants, significantly reduced immobility periods, indicating a potential benefit. Biochemical tests showed that these treatments lessened oxidative stress in the brain, restoring important antioxidant enzyme levels. Overall, the results point to antioxidants, including melatonin, as promising candidates for managing CFS symptoms.
Read More
Melatonin shows mixed benefits for fatigueEffect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
Potential biomarkers explored
We sought to understand how melatonin supplementation affects chronic fatigue syndrome among multiple sclerosis (MS) patients. In our study, 102 patients were divided into groups based on their treatment types and supplemented with melatonin for 90 days.
We found that melatonin significantly reduced plasma lipid hydroperoxide levels, which may relate to chronic fatigue in MS. However, homocysteine levels showed no significant change across the groups after treatment. Overall, while melatonin appeared beneficial in lowering certain biomarkers, it did not significantly alleviate fatigue symptoms in all MS patients.
Read More
We explored the effects of melatonin on chronic fatigue syndrome (CFS) in patients with Parkinson's disease. Our study involved 30 patients at different stages of the disease.
After treatment, we observed a significant 21% reduction in fatigue severity. Not only did sleep quality improve, but there was also a decrease in anxiety and an enhancement in overall quality of life.
However, we found no noteworthy changes in motor or cognitive functions, nor in depression levels. Melatonin appears promising as part of a treatment plan for CFS and sleep issues in these patients.
Read More